Meet our Board of Directors

Isaac Cheng, M.D.

Board Member

Isaac Cheng, M.D., is an Investment Professional with Morningside Ventures, which he joined in 2006 to focus on biopharmaceutical and healthcare investments. Dr. Cheng has served on numerous public and private company boards, including NuCana (NASDAQ: NCNA), Advanced Cell Diagnostics (sold to Bio-Techne), Liquidia Technologies, Incarda Therapeutics, Meissa Vaccines, Amylyx Pharmaceuticals, Cognoa, Artugen Therapeutics, Cognito Therapeutics, Atea Pharmaceuticals, Big Health, and Tallac Therapeutics. Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company that was sold to Allergan. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine.

Stephen Dilly, MBBS, Ph.D.

Board Member

Stephen Dilly, MBBS, Ph.D., is the President and Chief Executive Officer and has also been a member of the Board of Directors of Sierra Oncology since June 2020. Previously, Dr. Dilly spent three decades of executive management experience in the biopharmaceutical industry. Most recently, Dr. Dilly served as CEO and Board Member of Aimmune Therapeutics. He has served in executive roles at Genentech, Chiron, and SmithKline Beecham and has been associated with the development and launch of many marketed drugs across multiple therapeutic areas. Dr. Dilly also currently serves on the Board of Directors of several private companies. He holds an MBBS from the University of London and a Ph.D. in Cardiac Physiology from the University of London.

Kenneth Kelley, MBA

Board Member

Kenneth Kelley has over 35 years of entrepreneurial, venture capital, operational, and technical biotechnology experience. He currently serves on the Board of Directors of Mevox, ID Biologics, Meissa Vaccines, Public Health Vaccines, and publicly held Halozyme Therapeutics. Previously, Mr. Kelley was co-founder, CEO, and Chairman of PaxVax. Mr. Kelley was a venture capitalist at K2 BioVentures, Latterell Venture Partners, and Institutional Venture Partners (IVP) and has made over 40 biotechnology and medical startup investments. Mr. Kelley was a White House Presidential Executive Fellow from 2016-2017 as well as an Advanced Leadership Initiative (ALI) Fellow at Harvard University from 2015-2016. He earned an MBA from Stanford University and a B.A. in Biochemical Sciences from Harvard University.

Margaret Liu, M.D.

Board Member

Margaret Liu, M.D., has pioneered both bispecific antibody technology for cancer and DNA vaccines. Dr. Liu was the recipient of an NIH Physician-Scientist Award and has held appointments/adjunct appointments at the Massachusetts Institute of Technology, Harvard Medical School, the University of Pennsylvania, the Karolinska Institutet in Stockholm, and UCSF. She held leadership/executive positions at Merck Research Laboratories and Chiron Corporation, was Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation, Executive Vice-Chair of the International Vaccine Institute, and was on the US NIH NIAID Council. Dr. Liu obtained an M.D. from Harvard Medical School, a B.A. in Chemistry, summa cum laude, from Colorado College, and passed the Epreuve pour le Diplôme d’Enseignement, à l’unanimité (judges’ unanimous decision), in piano from the Ecole Normale de Musique de Paris.  She lectured at the invitation of the Nobel Committee and is the recipient of an honorary Doctor of Medicine from the Karolinska Institutet. She completed her clinical training at Massachusetts General Hospital/Harvard Medical School and received Board Certification in Internal Medicine and in Endocrinology and Metabolism.

Tyler Martin, M.D.

Chief Executive Officer and Chairman

Dr. Tyler Martin is the Chairman and CEO of Adjuvance Technologies. Prior to Adjuvance, Dr. Martin held senior leadership positions in a number of biotech companies including Chiron, Sangamo, and Dynavax Technologies. Dr. Martin has led teams that filed more than 100 Investigational New Drug (IND) Applications including two adjuvanted vaccines approved by major regulatory authorities, Fluad and Heplisav-B. Dr. Martin received his M.D. from the University of Nebraska, College of Medicine, and served as a Resident in Pediatrics at the University of Nebraska Medical Center.